Ross McDougall, M.D., Ch.B., Ph.D., receives SNMMI 2016 Georg Charles de Hevesy Award

June 12, 2016

San Diego, Calif. -- Ross McDougall, MB, ChB, PhD, professor emeritus of radiology and medicine at Stanford University, Stanford, Calif., has been named this year's recipient of the Georg Charles de Hevesy Nuclear Pioneer Award for his contributions to nuclear medicine. McDougall was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) at its 2016 Annual Meeting, held June 11-15 in San Diego, Calif.

McDougall has been associated with Stanford University Medical School from 1972, the first 2 years as a fellow and subsequently as full-time faculty. In 1989, he took over directorship of the thyroid clinic. McDougall was involved in both the Medical School and the hospital. He held numerous positions of importance at those institutions, including president of the medical center--the first faculty member elected to this post. He was director of the Nuclear Medicine Residency Program for 25 years. Since retiring as director of the thyroid clinic in 2008, he has been an active Emeritus professor.

"I was fortunate to train under Dr. McDougall while I was a resident at Stanford University in the mid-1990s," said SNMMI President Hossein Jadvar, MD, PhD, MPH, MBA, FACNM. "He is an exceptionally caring physician and a superb diagnostician. He exemplifies the true meaning of a gentleman and scholar."

McDougall conducted laboratory and clinical research and published more than 160 peer-reviewed papers and 110 book chapters, reviews and editorials. He authored or coauthored 3 textbooks on thyroid disease. He was appointed to the American Board of Nuclear Medicine, and he subsequently chaired the board for two years. He was vice chair of the Residency Review Committee in Nuclear Medicine. He was also a governor of the American Board of Internal Medicine for three years. He was president of the Western Regional Chapter of the Society of Nuclear Medicine and Molecular Imaging.

Multiple honors have been awarded to McDougall for his contributions to nuclear medicine. From the University of Glasgow, he received the Ure Prize and Cullen Medal for Pharmacology, the Captain Rankin V.C. Prize for Pathology, the Ure Prize and McFarlane Prize for the Integrated Year of Medicine and Surgery and the William Hunter Medal in Clinical Surgery. From Stanford, he received the Robert Reid Newell Award, the Arthur Bloomfield Award, the Alwin C. Rambar Award and the Albion Walter Hewlett Award. He received the Distinguished Scientist Award from the Western Regional Chapter of the Society of Nuclear Medicine and Molecular Imaging in 2006.

"The de Hevesy Award means an enormous amount to me," Ross McDougall said. "I spent more than 45 years in the field of nuclear medicine using tracers for diagnosis and therapy. I have been a colleague of three previous winners and have interacted with many others, all of whom I looked up to as giants in the field. I was shocked and stunned when I received notice of the award--and now, added to these sentiments, I am greatly honored and humbled. I hope over the years I did my very best to advance the specialty by teaching residents and fellows listening to patients. My deepest thanks to the Society."

McDougall received his MB and ChB degrees from the University of Glasgow. He passed the Membership Examination of the Royal College of Physicians and Surgeons in Glasgow in 1971 and subsequently became a Fellow of that college and the Royal College of Physicians in London. He was awarded a PhD in 1972 for clinical and radiobiological studies of 125I in the treatment of thyrotoxicosis. Some of this work was published in the Lancet and the New England Journal of Medicine. In 1972 he was awarded a Harkness Fellowship to conduct research at Stanford. He received two Carnegie Scholarships, one in 1964 to investigate DNA patterns of adrenal tumors at Glasgow Royal Infirmary, and a second in 1965 to investigate the lymphatic anatomy of adrenal glands at Howard University in Washington, D.C.

Each year, SNMMI presents the Georg Charles de Hevesy Nuclear Medicine Pioneer Award to an individual for outstanding contributions to the field of nuclear medicine. De Hevesy received the 1943 Nobel Prize in chemistry for his work in determining the absorption, distribution, metabolism and elimination of radioactive compounds in the human body. His work led to the foundation of nuclear medicine as a tool for diagnosis and therapy, and he is considered to be one of the fathers of nuclear medicine. SNMMI has given the de Hevesy Award every year since 1960 to honor groundbreaking discoveries and inventions in the field of nuclear medicine.

The list of previous recipients of this award includes numerous Nobel laureates--such as Ernest Lawrence, who invented the world's first cyclotron for the production of radionuclides, and Glenn Seaborg, who discovered more than half a dozen new elements.
-end-
About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.

SNMMI's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.

Society of Nuclear Medicine

Related Molecular Imaging Articles from Brightsurf:

New technique offers higher resolution molecular imaging and analysis
The new approach from Northwestern Engineering could help researchers understand more complicated biomolecular interactions and characterize cells and diseases at the single-molecule level.

Molecular imaging offers insight into therapy outcomes for neuroendocrine tumor patients
A new proof-of-concept study published in the May issue of The Journal of Nuclear Medicine has demonstrated that molecular imaging can be used for identifying early response to 177Lu-DOTATATE treatment in neuroendocrine tumor patients.

Non-invasive imaging method spots cancer at the molecular level
Researchers for the first time have combined a powerful microscopy technique with automated image analysis algorithms to distinguish between healthy and metastatic cancerous tissue without relying on invasive biopsies or the use of a contrast dye.

Molecular imaging suggests smokers may have impaired neuroimmune function
Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNM MI) shows preliminary evidence that tobacco smokers may have reduced neuroimmune function compared with nonsmokers.

Novel noninvasive molecular imaging for monitoring rheumatoid arthritis
A first-in-human Phase 1/Phase II study demonstrates that intravenous administration of the radiopharmaceutical imaging agent technetium-99m (99mTc) tilmanocept promises to be a safe, well-tolerated, noninvasive means of monitoring rheumatoid arthritis disease activity.

Improving molecular imaging using a deep learning approach
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed using a new deep learning approach to image reconstruction developed by researchers at Rensselaer Polytechnic Institute.

Nanoplatform developed with three molecular imaging modalities for tumor diagnosis
Nanotechnology and biotechnology are bringing us increasingly closer to personalised cancer treatment.

Study suggests molecular imaging strategy for determining molecular classifications of NSCLC
Recent findings suggest a novel positron emission tomography (PET) imaging approach determining epidermal growth factor receptor (EGFR) mutation status for improved lung cancer patient management.

New imaging technique able to watch molecular dynamics of neurodegenerative diseases
Researchers have developed a fast and practical molecular-scale imaging technique that could let scientists view never-before-seen dynamics of biological processes involved in neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.

Combined optical and molecular imaging could guide breast-conserving surgery
Breast-conserving surgery is the primary treatment for early-stage breast cancer, but more accurate techniques are needed to assess resection margins during surgery to avoid the need for follow-up surgeries.

Read More: Molecular Imaging News and Molecular Imaging Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.